Shamburg News · 8-K filed Nov 16, 2026, 8:12 AM EST
Akebia Therapeutics Enters $140 Million Senior Secured Term Loan with Symbiotic Capital
AKBA · Akebia Therapeutics, Inc.
- Material agreement
- Financing
- Other event
- Reg FD disclosure
- Materiality: high
On November 12, 2026, Akebia Therapeutics, Inc. entered into a Loan and Security Agreement with Symbiotic Capital lenders providing a senior secured term loan facility of up to $140.0 million, with a $60.0 million initial tranche funded at closing. The Company used the initial loan proceeds to repay in full its prior $55.0 million term loan with Kreos, and issued warrants for 3,441,352 common shares at an exercise price of $0.6974 per share. The Company stated that its existing cash resources are sufficient to fund its current operating plan for at least two years.
Source: SEC EDGAR, Form 8-K, Items 1.01, 1.02, 2.03, 3.02, 7.01, 8.01, accession 0001517022-26-000089.
Written from the filing by Shamburg Markets. Figures are as reported by the company.